bioCSL distributing transfusion testing tech in ANZ
CSL’s (ASX:CSL) vaccine subsidiary bioCSL has partnered with US-based Immucor to distribute transfusion testing technology in Australia and New Zealand.
bioCSL has commenced distribution of Immucor’s Capture antibody-detection technology platform and reagents in the two markets.
Capture is designed for the crossmatching of blood used for transfusion. It uses techniques that differ from those commonly used in Australia.
CSL said Capture delivers high levels of specificity - potentially reducing the need for additional testing and speeding up the process for patients awaiting a blood transfusion - and a high degree of sensitivity for detection of clinically significant antibodies.
The Immucor product range consists of around 2000 immunohaematology reagents, automated testing devices and Immucor’s supporting Immulink software.
“The advances offered by Capture build on our proud record of helping to maintain Australia and New Zealand’s excellent safety record in blood transfusion over the past 30 years,” bioCSL director for immunohaematology Allen Bollands said.
“We are confident that Australian and New Zealand immunohaematology leaders will experience benefits similar to their colleagues around the world.”
CSL (ASX:CSL) shares were trading 0.13% lower at $67.49 as of around 12 pm on Monday.
The last mile of life sciences innovation
How do we translate technological possibility into meaningful real-world impact?
Machine learning uncovers patterns in DNA methylation
A new machine-learning method identifies differentially methylated DNA regions without sample...
HRT linked to lower dementia risk in some women
Hormone replacement therapy may reduce the risk of dementia — particularly for certain...
